Lurbinectedin Study Shows SingleAgent Potential in SecondLine SCLC

Lurbinectedin Study Shows Single-Agent Potential in Second-Line SCLC

Anna F. Farago, MD, PhD, discusses the second-line data with lurbinectedin and its potential impact on the small cell lung cancer field.

Original Article: Lurbinectedin Study Shows Single-Agent Potential in Second-Line SCLC

More From BioPortfolio on "Lurbinectedin Study Shows Single-Agent Potential in Second-Line SCLC"